Funder: National Institutes of Health
Due Dates: July 2, 2025 (New) | August 4, 2025 (Renewal/Resubmission/Revision) | November 3, 2025 (New) | December 2, 2025 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $500,000 direct costs/year for each phase; R61 phase (up to 2 years), R33 phase (up to 3 years); max 5 years total.
Summary: Supports development of novel interdisciplinary research infrastructure to advance aging science, using a two-phase R61/R33 mechanism.
Key Information: Both R61 and R33 phases must be proposed; annual direct costs must remain under $500,000; clinical trials are optional.